Featured Publications
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal Of Psychiatry 2021, 178: 352-362. PMID: 33653121, DOI: 10.1176/appi.ajp.2020.20010018.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusionAnnual Research Review: Defining and treating pediatric treatment‐resistant depression
Dwyer JB, Stringaris A, Brent DA, Bloch MH. Annual Research Review: Defining and treating pediatric treatment‐resistant depression. Journal Of Child Psychology And Psychiatry 2020, 61: 312-332. PMID: 32020643, PMCID: PMC8314167, DOI: 10.1111/jcpp.13202.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionMajor depressive disorderAdolescent treatment-resistant depressionRisk factorsAdolescent major depressive disorderPsychotherapy treatment trialSecond-line treatmentSignificant risk factorsPediatric clinical trialsSecond leading causeSignificant health problemEvidence-based psychotherapiesCent of adolescentsMedication switchAdequate medicationSubstantial morbiditySymptom improvementInterventional treatmentMedication augmentationTreatment trialsCare treatmentClinical trialsDepressive disorderDiagnostic difficultiesLeading causeMeta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder
Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular Psychiatry 2009, 15: 850-855. PMID: 19468281, PMCID: PMC2888928, DOI: 10.1038/mp.2009.50.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsY-BOCS scoresSerotonin reuptake inhibitorsObsessive-compulsive disorderHigh dosesReuptake inhibitorsTreatment respondersDose of SSRIsTreatment efficacyDouble-blind placebo-controlled clinical trialGreater side effect burdenPlacebo-controlled clinical trialSide effect burdenAbsolute risk differenceTreatment of adultsGreater treatment efficacyMajor depressive disorderImproved treatment efficacyTreatment of OCDDose-response relationshipRevMan 4.2.8Clinical trialsDepressive disorderCause dropoutsMean changeEfficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer J, Landeros-Weisenberger A, Johnson J, Londono Tobon A, Flores J, Nasir M, Couloures K, Sanacora G, Bloch M. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. FOCUS The Journal Of Lifelong Learning In Psychiatry 2022, 20: 241-251. PMID: 37153136, PMCID: PMC10153503, DOI: 10.1176/appi.focus.22020004.Peer-Reviewed Original ResearchTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusion
2017
Hippocampal Volume Changes Following Electroconvulsive Therapy: A Systematic Review and Meta-analysis
Wilkinson ST, Sanacora G, Bloch MH. Hippocampal Volume Changes Following Electroconvulsive Therapy: A Systematic Review and Meta-analysis. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2017, 2: 327-335. PMID: 28989984, PMCID: PMC5627663, DOI: 10.1016/j.bpsc.2017.01.011.Peer-Reviewed Original ResearchMajor depressive disorderElectroconvulsive therapyTotal hippocampal volumeHippocampal volumeStandardized mean differenceConsistent morphological findingsHippocampal volume increasesCognitive side effectsPre-treatment valuesHippocampal volume changesRandom-effects modelMechanism of actionClinical improvementPrimary outcomeECT treatmentDepressive disorderEffective therapyNeuroplastic processesECT studiesSide effectsAnimal modelsDepression symptomsMeta-AnalysisSystematic reviewMorphological findings
2016
Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial.
Coughlin CG, Jakubovski E, Bloch MH. Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial. The Journal Of Clinical Psychiatry 2016, 77: e1262-e1269. PMID: 27631142, DOI: 10.4088/jcp.15m10075.Peer-Reviewed Original ResearchConceptsMajor depressive disorderCitalopram treatmentSuicidal ideationClinical predictorsClinical variablesSelective serotonin reuptake inhibitorsNonpsychotic major depressive disorderFirst-line treatmentBaseline clinical variablesSerotonin reuptake inhibitorsWeeks of treatmentSequenced Treatment AlternativesSide effect dataGreater likelihoodTime coursePhase 1Cardiac comorbiditiesNeurologic comorbiditiesBaseline characteristicsSedative medicationsReuptake inhibitorsTrial phase 1Clinical correlatesQuick InventoryDepressive disorderEarly onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. The Journal Of Clinical Psychiatry 2016, 77: e605-11. PMID: 27249090, DOI: 10.4088/jcp.14r09758.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsYale-Brown Obsessive Compulsive ScalePlacebo-controlled trialSerotonin reuptake inhibitorsTreatment of adultsObsessive-compulsive disorderSSRI responseSSRI treatmentReuptake inhibitorsSymptom improvementEfficacy of SSRIsTrials of SSRIsFirst-line pharmacologic treatmentCochrane Central RegisterStart of treatmentMajor depressive disorderEffect of doseObsessive Compulsive ScaleSSRI actionCentral RegisterPharmacologic treatmentPrimary outcomeControlled TrialsSSRI trialDepressive disorder
2015
Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder
Jakubovski E, Varigonda AL, Freemantle N, Taylor MJ, Bloch MH. Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. American Journal Of Psychiatry 2015, 173: 174-183. PMID: 26552940, PMCID: PMC4975858, DOI: 10.1176/appi.ajp.2015.15030331.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsMajor depressive disorderSerotonin reuptake inhibitorsDepressive disorderHigh dosesTreatment responseReuptake inhibitorsBenefit of SSRIsEfficacy of SSRIsTolerability of SSRIsEffects of SSRIsRandomized placebo-controlled trialPlacebo-controlled trialStratified subgroup analysisTherapeutic dose rangeDose-response relationshipSSRI doseTolerability analysisMedication dosesSignificant positive associationSubgroup analysisMultiple time pointsDose categoriesMixed regression modelsCause dropoutsObsessive–compulsive symptoms are associated with psychiatric comorbidities, behavioral and clinical problems: a population-based study of Brazilian school children
Alvarenga PG, do Rosario MC, Cesar RC, Manfro GG, Moriyama TS, Bloch MH, Shavitt RG, Hoexter MQ, Coughlin CG, Leckman JF, Miguel EC. Obsessive–compulsive symptoms are associated with psychiatric comorbidities, behavioral and clinical problems: a population-based study of Brazilian school children. European Child & Adolescent Psychiatry 2015, 25: 175-182. PMID: 26015374, DOI: 10.1007/s00787-015-0723-3.Peer-Reviewed Original ResearchConceptsFamily History ScreenObsessive-compulsive disorderObsessive-compulsive symptomsSchool-aged childrenChild Behavior ChecklistUnaffected controlsPediatric-onset obsessive-compulsive disorderPresence of OCSPopulation-based studyComorbid psychiatric disordersMajor depressive disorderWell-Being AssessmentOCD groupBrazilian school childrenGroup of childrenPsychiatric comorbidityDepressive disorderClinical impactFunctional impairmentPsychiatric disordersClinical problemOCS groupDiagnostic groupsSignificant socio-demographic differencesSocio-demographic differencesSystematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder
Varigonda AL, Jakubovski E, Taylor MJ, Freemantle N, Coughlin C, Bloch MH. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 2015, 54: 557-564. PMID: 26088660, DOI: 10.1016/j.jaac.2015.05.004.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsPediatric major depressive disorderMajor depressive disorderSerotonin reuptake inhibitorsSSRI agentsReuptake inhibitorsPediatric depressionDepressive disorderAdult major depressive disorderFirst-line pharmacological treatmentEarly treatment responseIndividual patient dataStandardized mean differenceMDD trialsSSRI doseSSRI pharmacotherapyPlacebo groupAdult patientsSSRI responsePharmacological treatmentPharmacological trialsTreatment responsePooled estimatesPharmacological responseHigh doses
2014
Prognostic subgroups for citalopram response in the STAR*D trial.
Jakubovski E, Bloch MH. Prognostic subgroups for citalopram response in the STAR*D trial. The Journal Of Clinical Psychiatry 2014, 75: 738-47. PMID: 24912106, PMCID: PMC4471174, DOI: 10.4088/jcp.13m08727.Peer-Reviewed Original ResearchConceptsMajor depressive disorderBaseline clinical characteristicsClinical characteristicsTreatment successTreatment outcomesTreatment responseSide effectsSelective serotonin reuptake inhibitor (SSRI) pharmacotherapyEarly symptom improvementInitial clinical characteristicsOpen-label citalopramPrimary outcome measureFirst treatment phasePast treatment historySequenced Treatment AlternativesDSM-IV diagnosisTraditional psychiatric diagnosesDifferential treatment outcomesSSRI treatmentSymptom improvementMDD patientsMedication responsePoor responseDepressive disorderPrognostic subgroups
2013
Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive–compulsive disorder and a history of major depressive disorder
Niciu MJ, Grunschel B, Corlett PR, Pittenger C, Bloch MH. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive–compulsive disorder and a history of major depressive disorder. Journal Of Psychopharmacology 2013, 27: 651-654. PMID: 23676198, DOI: 10.1177/0269881113486718.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderAntidepressant effectsPsychiatric comorbidityComorbid depressionNon-competitive N-methyl-D-aspartate (NMDA) receptor antagonistN-methyl-D-aspartate receptor antagonistTreatment-refractory obsessive-compulsive disorderAcute antidepressant effectsTreatment-resistant unipolarOpen-label trialSevere respiratory depressionAdverse neuropsychiatric effectsComorbid psychiatric disordersMinimal depressive symptomsOff-label useMajor depressive disorderStart of infusionRespiratory depressionIntravenous ketamineNeuropsychiatric effectsKetamine infusionBipolar depressionReceptor antagonistDepressive disorderSedative effects
2011
Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis
Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Molecular Psychiatry 2011, 17: 1272-1282. PMID: 21931319, PMCID: PMC3625950, DOI: 10.1038/mp.2011.100.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialMajor depressive disorderBaseline depression severityDepression severityPublication biasMethodological qualityGreater baseline depression severityDocosahexaenoic acidEicosapentaenoic acidTrial methodological qualityPrimary outcome measureNon-significant benefitTreatment of depressionLow methodological qualityFatty acid treatmentTreat analysisDepressive disorderMajor depressionSources of heterogeneityOutcome measuresClinical measuresTreatment efficacySystematic reviewSecondary analysisStudy participantsThe Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis
Hannestad J, DellaGioia N, Bloch M. The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis. Neuropsychopharmacology 2011, 36: 2452-2459. PMID: 21796103, PMCID: PMC3194072, DOI: 10.1038/npp.2011.132.Peer-Reviewed Original ResearchConceptsMajor depressive disorderInflammatory cytokinesSerum levelsAntidepressant treatmentInterleukin-6Depressive symptomsIL-1βCytokine levelsDepressive episodeDiagnosis of MDDTumor necrosis factor alphaPharmacological antidepressant treatmentAntidepressant medication treatmentClasses of antidepressantsStratified subgroup analysisIL-1 betaNecrosis factor alphaNormalization of levelsReuptake inhibitorsMedication treatmentPharmacological treatmentSubgroup analysisBrain dysfunctionDepressive disorderFactor alpha
2010
Time-Lag Bias in Trials of Pediatric Antidepressants: A Systematic Review and Meta-Analysis
Reyes MM, Panza KE, Martin A, Bloch MH. Time-Lag Bias in Trials of Pediatric Antidepressants: A Systematic Review and Meta-Analysis. Journal Of The American Academy Of Child & Adolescent Psychiatry 2010, 50: 63-72. PMID: 21156271, PMCID: PMC3645909, DOI: 10.1016/j.jaac.2010.10.008.Peer-Reviewed Original ResearchConceptsSerotonin reuptake inhibitorsPlacebo-controlled trialTime-lag biasMajor depressive disorderYears of ageReuptake inhibitorsAntidepressant trialsPediatric depressionDepressive disorderTreatment respondersMAIN OUTCOMESystematic reviewMeta-AnalysisPositive findingsNegative findingsNegative trialsMedical literatureAntidepressantsTrialsPublication of findingsNegative resultsChild psychiatryEfficacyFindingsPublication time